Summary

A novel platinum-chromium everolimus-eluting stent proved to be as safe and effective as the cobalt-chromium everolimus-eluting stent in the 12-month Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions Trial [PLATINUM; NCT00823212], the first large-scale, international, multicenter, prospective, single-blind, randomized trial of the novel stent [Stone GW et al. J Am Coll Cardiol 2011].